Allergology International

This is a promotion site for the
Allergology International. You can see
the journal contents in Science Direct

Current Issue |
Volume 72, Issue 2
April 2023

Cover of Allergology International

Open Access ISSN: 1323-8930
2021 Impact Factor: 7.478
View More on Journal Insights
© 2023 Journal Citation Reports
© Clarivate Analytics, 2023

Appreciation to Reviewers

The Editors are deeply appreciative of their valuable expertise and contributions to AI. See more

Outstanding Reviewers 2021

About Allergology International

Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense.

The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following three categories: Original Articles, Review Articles, and Letters to the Editor.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

Editor's Choices

Original Article

Editor’s comment: Asthma treatment has evolved in recent years, with the widespread use of inhaled corticosteroids and biological agents. However, for some patients, oral corticosteroids (OCS) are still the treatment of choice. Ryu et al. investigated an association between lifetime OCS exposure with frailty and muscle weakness among elderly patients with asthma. They found that cumulative lifetime OCS exposure was associated with a higher prevalence of frailty and muscle weakness, indicating the importance of minimizing lifetime OCS exposure for prolonging healthy life expectancy in patients with asthma.

Original Article

Editor’s comment: Natto, a famous Japanese dish prepared by fermenting soybeans, can sometimes cause anaphylaxis. Epicutaneous sensitization to poly-γ-glutamic acid (PGA) by jellyfish stings is known to contribute to the sensitization to natto. Suzuki et al. examined the antigenicity of nattokinase, a subtilisin family serine protease, in patients who had natto allergy but were negative to PGA on a skin prick test. They found that a substantial number of PGA-non-sensitized patients were sensitized to nattokinase.

Original Article

Editor’s comment: Schnitzler syndrome is a rare disorder characterized by recurrent febrile rash, bone and joint pain, fatigue, and systemic inflammatory responses with leukocytosis, enlarged lymph nodes, and a monoclonal IgM component. Takimoto-Ito et al. performed a nationwide survey of major dermatology departments in Japan along with a systematic search of PubMed and Ichushi-Web for Schnitzler syndrome. In Japan, they found 36 clinically diagnosed cases from 1994 through the spring of 2022, with a male-to-female ratio of 1:1. They summarized characteristics of these patients, including symptoms, responses to various treatments, and prognosis.

Review Series: The latest findings on ILC2s, from bench to bedside

In this issue, Yashiro, Iwata, and Imai provide reviews concerning ILC2s from the perspectives of basic researchers, allergologists, and dermatologists, respectively.

Invited Review Article

Yashiro et al. review in detail the regulatory factors of ILC2s identified in mice, further discussing the role of ILC2s in various diseases as well as in allergies.

Invited Review Article

Iwata et al. summarize recent findings on the characteristics and functions of human lung ILC2s, describing their clinical significance in bronchial asthma.

Invited Review Article

Imai describes ILC2s in the skin, which have a completely different activation mechanism than ILC2s in the lung and discusses their potential as targets for monoclonal antibody therapy. Because ILC2s are tissue-resident cells with different phenotypes depending on the tissue, the characteristics of ILC2s in each tissue must be considered when determining therapeutic targets to suppress ILC2s.

To Top